Retiform Plaques: An Additional Diagnostic Consideration

Main Article Content

Hannah Mumber
Department of Dermatology, Hospital of University of Pennsylvania, Philadelphia, PA

Jimmy Lam
Lynne Goldberg
Christina Lam

Keywords

retiform plaques, linear morphea, diagnostic challenge, quality of life, autoimmune condition

References

1. “The Skin in Immune, Autoimmune, Autoinflammatory, and Rheumatic Disorders.” Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, by Klaus Wolff et al., McGraw-Hill Education, 2017, pp. 343–364.

2. Ee HL, Tan SH. Reticulate hyperpigmented scleroderma: a new pigmentary manifestation. Clin Exp Dermatol. 2005;30(2):131-133. doi:10.1111/j.1365-2230.2004.01683.x

3. Weibel L, Harper JI. Linear morphoea follows Blaschko’s lines. Br J Dermatol. 2008;159(1):175-181. doi:10.1111/j.1365-2133.2008.08647.x

4. Wolf R, Wolf D, Ruocco E, et al. Wolf’s isotopic response. Clin Dermatol. 2011;29(2):237-240. doi:10.1016/j.clindermatol.2010.09.015

5. Sartori-Valinotti JC, Tollefson MM, Reed AM. Updates on morphea: role of vascular injury and advances in treatment. Autoimmune Dis. 2013;467808. doi:10.1155/2013/467808

6. O’Brien JC, Nymeyer H, Green A, et al. Changes in disease activity and damage over time in patients with morphea. JAMA Dermatology. April 2020. doi:10.1001/jamadermatol.2020.0034

Article Sidebar

PDF
Published
Mar 18, 2024
DOI https://doi.org/10.25251/skin.8.2.20

Article Details

How to Cite
[1]
Mumber, H., Lam, J., Goldberg, L. and Lam, C. 2024. Retiform Plaques: An Additional Diagnostic Consideration. SKIN The Journal of Cutaneous Medicine. 8, 2 (Mar. 2024), 1461–1463. DOI:https://doi.org/10.25251/skin.8.2.20.
Issue
Vol. 8 No. 2 (2024): March 2024 Issue
Section
Short Communications
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.